Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[What is a mild cognitive impairment?].

Florence Portet1, Pierre-Jean Ousset, Jacques Touchon

  • 1Centre mémoire ressources et recherche (CM2R) du Languedoc-Roussillon, neurologie B, Inserm E 361, CHU de Montpellier, 34295 Montpellier. floportet@aol.com

La Revue Du Praticien
|January 7, 2006
PubMed
Summary

Mild cognitive impairment (MCI) is a complex condition with varied causes and outcomes. New proposed criteria aim to refine MCI diagnosis for research and clinical practice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study.

Free radical biology & medicine·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative.

Alzheimer's research & therapy·2025
Same author

Harnessing combination therapy: Current treatments, recent advancements, and future directions in Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2025
Same author

Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.

The journal of prevention of Alzheimer's disease·2025
Same author

Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC.

Alzheimer's research & therapy·2025

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Context:

  • Mild cognitive impairment (MCI) is recognized as an intermediate stage between normal cognition and dementia.
  • Existing definitions of MCI present heterogeneity in etiological factors, clinical symptoms, and disease progression.

Purpose:

  • To propose refined diagnostic criteria for MCI.
  • To enhance the utility of MCI classification in research and clinical settings.

Summary:

  • MCI is characterized by cognitive complaints, a reported decline in cognitive/functional performance, and clinically evident cognitive deficits.
  • Crucially, MCI does not significantly impair daily life activities and is distinct from dementia.
  • Proposed criteria address the heterogeneity of MCI by focusing on specific diagnostic features.

Impact:

  • The refined criteria aim to improve the consistency and accuracy of MCI diagnosis.
  • This could lead to better patient stratification for clinical trials and therapeutic interventions.
  • Standardized MCI criteria will facilitate more precise research into cognitive aging and neurodegenerative diseases.

Related Experiment Videos